<bill session="116" type="s" number="466" updated="2019-10-16T13:58:49Z">
  <state datetime="2019-02-13">REFERRED</state>
  <status>
    <introduced datetime="2019-02-13"/>
  </status>
  <introduced datetime="2019-02-13"/>
  <titles>
    <title type="official" as="introduced">A bill to provide that certain guidance related to waivers for State innovation under the Patient Protection and Affordable Care Act shall have no force or effect.</title>
    <title type="short" as="introduced">Protecting Americans with Pre-existing Conditions Act of 2019</title>
    <title type="short" as="introduced">Protecting Americans with Pre-existing Conditions Act of 2019</title>
    <title type="display">Protecting Americans with Pre-existing Conditions Act of 2019</title>
  </titles>
  <sponsor bioguide_id="W000805"/>
  <cosponsors>
    <cosponsor bioguide_id="B001230" joined="2019-02-13"/>
    <cosponsor bioguide_id="B001277" joined="2019-05-21"/>
    <cosponsor bioguide_id="B001288" joined="2019-05-21"/>
    <cosponsor bioguide_id="C000141" joined="2019-02-13"/>
    <cosponsor bioguide_id="C001070" joined="2019-05-21"/>
    <cosponsor bioguide_id="C001088" joined="2019-05-21"/>
    <cosponsor bioguide_id="D000563" joined="2019-05-15"/>
    <cosponsor bioguide_id="G000555" joined="2019-05-21"/>
    <cosponsor bioguide_id="H001075" joined="2019-05-15"/>
    <cosponsor bioguide_id="H001076" joined="2019-05-21"/>
    <cosponsor bioguide_id="H001042" joined="2019-05-21"/>
    <cosponsor bioguide_id="K000384" joined="2019-10-15"/>
    <cosponsor bioguide_id="K000367" joined="2019-05-21"/>
    <cosponsor bioguide_id="M001176" joined="2019-06-18"/>
    <cosponsor bioguide_id="M001169" joined="2019-05-13"/>
    <cosponsor bioguide_id="P000595" joined="2019-06-18"/>
    <cosponsor bioguide_id="S001194" joined="2019-05-21"/>
    <cosponsor bioguide_id="S001181" joined="2019-02-13"/>
    <cosponsor bioguide_id="S001203" joined="2019-05-21"/>
    <cosponsor bioguide_id="S000770" joined="2019-05-15"/>
    <cosponsor bioguide_id="T000464" joined="2019-05-21"/>
    <cosponsor bioguide_id="V000128" joined="2019-05-21"/>
    <cosponsor bioguide_id="W000779" joined="2019-05-21"/>
  </cosponsors>
  <actions>
    <action datetime="2019-02-13">
      <text>Introduced in Senate</text>
    </action>
    <action datetime="2019-02-13" state="REFERRED">
      <text>Read twice and referred to the Committee on Finance.</text>
    </action>
  </actions>
  <committees>
    <committee subcommittee="" code="SSFI" name="Senate Finance" activity="Referral"/>
  </committees>
  <relatedbills>
    <bill type="h" session="116" relation="unknown" number="1884"/>
    <bill type="h" session="116" relation="identical" number="986"/>
  </relatedbills>
  <subjects>
    <term name="Health"/>
    <term name="Administrative law and regulatory procedures"/>
    <term name="Department of Health and Human Services"/>
    <term name="Department of the Treasury"/>
    <term name="Health care costs and insurance"/>
    <term name="Health care coverage and access"/>
    <term name="State and local government operations"/>
  </subjects>
  <amendments/>
  <summary date="2019-02-13T05:00:00Z" status="Introduced in Senate">Protecting Americans with Pre-existing Conditions Act of 2019

This bill nullifies the Department of the Treasury and the Department of Health and Human Services guidance titled "State Relief and Empowerment Waivers," published on October 24, 2018. The guidance pertains to Section 1332 waivers (also known as State Innovation Waivers or State Relief and Empowerment Waivers), which allow states to forego certain requirements of the Patient Protection and Affordable Care Act in order to implement experimental plans for health care coverage, as long as the resulting coverage meets certain statutory criteria.

The guidance, which supersedes earlier guidance from 2015, alters agency interpretation of how states may satisfy the statutory criteria for waiver approval. For example, the guidance (1) redefines acceptable coverage under such waivers to include short-term, limited-duration insurance and association health plans; (2) allows the comprehensiveness and affordability of coverage under such waivers to be assessed based on projected availability, rather than enrollment; and (3) allows the level of coverage to be assessed based on the effects over the entire course of the waiver, rather than per year.</summary>
  <committee-reports/>
</bill>
